We are a leading provider of GLP/GCP compliant accelerator mass spectrometry (AMS) services to the global pharmaceutical and life science industries. Our customers use AMS services to overcome challenges they face in drug development, including assessment of pharmacokinetics, metabolism and mass balance.
AMS is an ultrasensitive detection platform capable of quantifying 14C-labeled molecules in the 0.001-100 DPM/mL range. Accium launched the first commercial AMS facility in North America in early 2006. We offer the most sensitive AMS service available to the pharmaceutical industry. Our services are used by five of the top ten global pharmaceutical companies including Merck, Novartis and Bristol-Myers Squibb.
Accium delivers its services through the AMS, Bioanalytical and Quality service units. Customers can mix and match services from any service unit in order to achieve the right outcome at the right cost. This efficient model enables Accium to offer the lowest cost AMS service available anywhere in the world. In addition, Accium's DirectAMS program makes AMS more accessible and more affordable than ever before.
Absolute Bioavailability Studies by AMS
"The CV and accuracy were 3.4-8.5% and 94-108% (82-119% for the lower limit of quantitation (LLOQ)), respectively, with a correlation coefficient of 0.9998....The precision and accuracy of quality controls and calibration standards met the requirements of bioanalytical guidance (FDA Guidance for Industry: Bioanalytical Method Validation, May 2001)."
Quantitation of 14C-Temozolomide in Tumors of Newly Diagnosed Glioblastoma Multiforme Patients
We are pleased to announce the initiation of an internal clinical study to quantify tumor uptake of 14C-Temozolomide (Temodar) and subsequent 14C-methylation of tumor DNA. The primary objective of the study is to evaluate a series of pharmacologic endpoints (biomarkers) as predictors of Temozolomide efficacy in individual patients. Predictive biomarkers, also known as companion diagnostic tests, help to identify the right treatment for each patient and may help improve overall outcome. Our neurosurgeon collaborator, Dr. Greg Foltz at Swedish Neuroscience Institute in Seattle, is providing surgical expertise and patient care at the Swedish Medical Center located adjacent to Accium's AMS facility.